pubmed.ncbi.nlm.nih.gov

Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections - PubMed

  • ️Sat Jan 01 2011

Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections

A Desirée Labeaud et al. Popul Health Metr. 2011.

Abstract

Background: Globally, arthropod-borne virus infections are increasingly common causes of severe febrile disease that can progress to long-term physical or cognitive impairment or result in early death. Because of the large populations at risk, it has been suggested that these outcomes represent a substantial health deficit not captured by current global disease burden assessments.

Methods: We reviewed newly available data on disease incidence and outcomes to critically evaluate the disease burden (as measured by disability-adjusted life years, or DALYs) caused by yellow fever virus (YFV), Japanese encephalitis virus (JEV), chikungunya virus (CHIKV), and Rift Valley fever virus (RVFV). We searched available literature and official reports on these viruses combined with the terms "outbreak(s)," "complication(s)," "disability," "quality of life," "DALY," and "QALY," focusing on reports since 2000. We screened 210 published studies, with 38 selected for inclusion. Data on average incidence, duration, age at onset, mortality, and severity of acute and chronic outcomes were used to create DALY estimates for 2005, using the approach of the current Global Burden of Disease framework.

Results: Given the limitations of available data, nondiscounted, unweighted DALYs attributable to YFV, JEV, CHIKV, and RVFV were estimated to fall between 300,000 and 5,000,000 for 2005. YFV was the most prevalent infection of the four viruses evaluated, although a higher proportion of the world's population lives in countries at risk for CHIKV and JEV. Early mortality and long-term, related chronic conditions provided the largest DALY components for each disease. The better known, short-term viral febrile syndromes caused by these viruses contributed relatively lower proportions of the overall DALY scores.

Conclusions: Limitations in health systems in endemic areas undoubtedly lead to underestimation of arbovirus incidence and related complications. However, improving diagnostics and better understanding of the late secondary results of infection now give a first approximation of the current disease burden from these widespread serious infections. Arbovirus control and prevention remains a high priority, both because of the current disease burden and the significant threat of the re-emergence of these viruses among much larger groups of susceptible populations.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Countries having transmission of the four arthropod-borne viruses included in this study: yellow fever virus, Japanese encephalitis virus, chikungunya virus, and Rift Valley fever virus.

Figure 2
Figure 2

Schema of disease development and assessment of population-level disease parameters for arboviral infections. Among a general population, susceptible (nonimmune) persons who are exposed to the bite of infected/infectious arthropods will go on to develop infection, which may become symptomatic or remain nonsymptomatic. Transmission studies, usually based on serologic testing, provide evidence of past and present infections among the target population, but do not quantify human disease or disability. Symptomatic disease (acute and chronic) and cause-specific fatality may be tallied either actively (by public health outbreak investigations) or passively (by health care systems statistics or case series reports). The generalizability of the rates reported for complications (transition to chronic disease) and for arbovirus-related fatality can vary widely depending on the sampling frame, study design, duration of longitudinal follow-up, and accuracy of diagnostics used.

Similar articles

  • Measuring the global burden of chikungunya and Zika viruses: A systematic review.

    Puntasecca CJ, King CH, LaBeaud AD. Puntasecca CJ, et al. PLoS Negl Trop Dis. 2021 Mar 4;15(3):e0009055. doi: 10.1371/journal.pntd.0009055. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33661908 Free PMC article.

  • Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.

  • Tuberculosis.

    Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P. Bloom BR, et al. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.

  • The burden of disease among the global poor.

    Gwatkin DR, Guillot M, Heuveline P. Gwatkin DR, et al. Lancet. 1999 Aug 14;354(9178):586-9. doi: 10.1016/S0140-6736(99)02108-X. Lancet. 1999. PMID: 10470717

  • The Minderoo-Monaco Commission on Plastics and Human Health.

    Landrigan PJ, Raps H, Cropper M, Bald C, Brunner M, Canonizado EM, Charles D, Chiles TC, Donohue MJ, Enck J, Fenichel P, Fleming LE, Ferrier-Pages C, Fordham R, Gozt A, Griffin C, Hahn ME, Haryanto B, Hixson R, Ianelli H, James BD, Kumar P, Laborde A, Law KL, Martin K, Mu J, Mulders Y, Mustapha A, Niu J, Pahl S, Park Y, Pedrotti ML, Pitt JA, Ruchirawat M, Seewoo BJ, Spring M, Stegeman JJ, Suk W, Symeonides C, Takada H, Thompson RC, Vicini A, Wang Z, Whitman E, Wirth D, Wolff M, Yousuf AK, Dunlop S. Landrigan PJ, et al. Ann Glob Health. 2023 Mar 21;89(1):23. doi: 10.5334/aogh.4056. eCollection 2023. Ann Glob Health. 2023. PMID: 36969097 Free PMC article. Review.

Cited by

References

    1. CDC Viral Hemorrhagic Fevers Fact Sheet. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm accessed March 29, 2010.
    1. CDC Arboviral Encephalitides Fact Sheet. http://www.cdc.gov/ncidod/dvbid/Arbor/index.htm accessed July 12, 2010.
    1. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet. 2008;371:500–509. doi: 10.1016/S0140-6736(08)60238-X. - DOI - PubMed
    1. Sang RC, Dunster LM. The growing threat of arbovirus transmission and outbreaks in Kenya: a review. East Afr Med J. 2001;78:655–661. - PubMed
    1. Gubler D. The emergence of epidemic dengue fever and dengue hemorrhagic fever in the Americas: a case of failed public health policy. Rev Panam Salud Publica. 2005;17:221–224. doi: 10.1590/S1020-49892005000400001. - DOI - PubMed

LinkOut - more resources